secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001193125-25-283075
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase Q3 net loss $11.9M ($0.13/sh); advancing IKT-001 Ph2b in PAH
-----------------------------------------------------------------------

- Net loss $11.9M for Q3 2025 vs $5.8M YoY; cash $77.3M at Sep 30, down from $97.5M at Dec 2024.
- R&D expenses $7.6M (Q3) vs $4.2M; includes $7.4M IPR&D write-off from CorHepta acquisition.
- Plans to initiate Phase 2b IMPROVE-PAH trial of IKT-001 in Q4 2025 (150 pts; 300/500 mg or placebo).
- Appointed Timothy Pigot as Chief Commercial and Strategy Officer.
- To present at Jefferies Global Healthcare Conference on Nov 17, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525283075/0001193125-25-283075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525283075/d93377d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-283075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer